Life sciences executive to join Patheon
Gilles Cottier to lead the company’s PDS business.
Patheon has appointed Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division effective immediately. He will serve as a member of Patheon’s executive committee and will report to Patheon CEO James Mullen.
The appointment of Cottier is part of a larger realignment effort by the company to create three distinct business segments – drug product services (DPS), drug substance services (DSS) and PDS. This will help the company forge deeper relationships with clients and employ new business models to help clients simplify their supply chain management activities. Patheon’s three business segments are led by key executives: Franco Negron for DPS, Lukas Utiger for DSS and now Cottier for PDS.
Cottier will assume the responsibilities for the PDS business from Michael Lehmann who was leading both Global PDS and Global Sales and Marketing. Lehmann will now focus on the Sales and Marketing function to support the expanding number of new business opportunities and increasing complexity of client relationships.
“Gilles brings a wealth of relevant experience in the life science and technology sector, including the manufacture of chemical and biochemical compounds, contract manufacturing and commercial services,” said Mullen. “I’d also like to thank Mike Lehmann for his outstanding leadership of the PDS business during his tenure. We established ourselves as the global market leader of PDS services.”
Cottier joins Patheon from Sigma-Aldrich Corporation where he was executive vice president and president of the Sigma-Aldrich Fine Chemicals (SAFC) Commercial Unit overseeing the contract manufacturing and the commercial services business unit which achieved more than $700 million in sales in 2014.
Cottier held numerous positions of increasing responsibility at Sigma-Aldrich during his more than 25 years with the company. He earned a master’s degree in organic chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon, France and advanced management program from the Harvard Business School in Boston, MA.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.